Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy:review,consensus recommendations and guidance for clinical practice  

作　　者：Nor Fariza Ngah Nor Asiah Muhamad Roslin Azni Abdul Aziz Shelina Oli Mohamed Nor Azita Ahmad Tarmizi Azian Adnan Zalifah Zakiah Asnir Zanariah Hussein Hui Foo Siew Masni Mohamed Noor Aliza Lodz Vijayamala Valayatham 

机构地区：[1]Institute for Clinical Research,National Institutes of Health,Setia Alam,Selangor 40790,Malaysia [2]Hospital Shah Alam,Selangor 40000,Malaysia [3]Sector for Evidence-Based Healthcare,National Institutes of Health,Setia Alam,Selangor 40790,Malaysia [4]Hospital Kuala Lumpur,Wilayah Persekutuan Kuala Lumpur 50586,Malaysia [5]Hospital Selayang,Selangor 68100,Malaysia [6]Hospital Ampang,Selangor 68000,Malaysia [7]Hospital Putrajaya,Wilayah Persekutuan Putrajaya 62250,Malaysia [8]Institute for Public Health,National Institutes of Health,Setia Alam,Selangor 40790,Malaysia

出　　处：《International Journal of Ophthalmology(English edition)》2022年第12期2001-2008,共8页国际眼科杂志（英文版）

摘　　要：The prevalence of diabetic retinopathy(DR),and associated morbidity is high in the Asia-Pacific region.Emerging evidence suggests a potential role for fenofibrate in the prevention of progression of DR,especially in patients with cardiovascular risk,and pre-existing mild-to-moderate DR.Fenofibrate has also been found to reduce maculopathy,and the need for laser treatment in these patients.Considering these benefits of fenofibrate,a group of experts from the fields of endocrinology and ophthalmology convened in May 2017,to discuss on the the mechanism of action,and clinical efficacy of fenofibrate in DR.The findings from key clinical studies on fenofibrate in DR were reviewed by the experts,and consensus statements were derived to define the role of fenofibrate in the prevention and treatment of DR.The statements were rated based on the GRADE criteria.An algorithm was also developed for the screening and treatment of DR in patients with type 2 diabetes(T2D),and the place of fenofibrate was defined in the algorithm.The expert recommendations,and the algorithm provided in this review will serve as a guide to the clinicians to reconsider the adjunctive use of fenofibrate for preventing the progression of DR in selected T2D patients.

关 键 词：diabetic retinopathy FENOFIBRATE consensus recommendations 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]